We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Syncona Limited | LSE:SYNC | London | Ordinary Share | GG00B8P59C08 | ORD NPV |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.40 | 0.32% | 126.40 | 126.00 | 126.40 | 127.00 | 124.00 | 124.00 | 115,523 | 15:00:25 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Trust,ex Ed,religious,charty | -39.79M | -56.02M | -0.0840 | -14.88 | 833.42M |
TIDMSYNC
RNS Number : 1357C
Syncona Limited
13 June 2019
13 June 2019
Syncona Limited
Dividend Announcement
The Directors of Syncona Limited have declared that a scrip dividend for the year ended 31 March 2019 of 2.3 pence per ordinary share will be paid on 29 July 2019 to those shareholders on the register of members of the Company as at 21 June 2019* (ex-dividend date 20 June 2019).
* note that this represents a correction from the record date of 20 June 2019 previously published at 07:00 on 13 June 2019 via RNS Number 0375C.
[ENDS]
Enquiries
Syncona Ltd
Annabel Clay / Siobhan Weaver
Tel: +44 (0) 20 3981 7940
FTI Consulting
Brett Pollard / Ben Atwell / Natalie Garland-Collins
Tel: +44 (0) 20 3727 1000
About Syncona:
Syncona is a leading FTSE250 healthcare company focused on founding, building and funding global leaders in life science. Our vision is to deliver transformational treatments to patients in truly innovative areas of healthcare while generating superior returns for shareholders.
We seek to partner with the best, brightest and most ambitious minds in science to build globally competitive businesses. We take a long-term view, underpinned by a deep pool of capital, and are established leaders in gene and cell therapy. We focus on delivering dramatic efficacy for patients in areas of high unmet need.
Copies of this press release, a company results presentation, and other corporate information can be found on the company website at: www.synconaltd.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
DIVBXGDLUDBBGCX
(END) Dow Jones Newswires
June 13, 2019 09:27 ET (13:27 GMT)
1 Year Syncona Chart |
1 Month Syncona Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions